Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase ...

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression .

U.S. military’s war with drugs: Drugs issued by military led to assaults, murders, doctors say

Nearly 8 per cent of active-duty army personnel are now on sedatives and more than 6 per cent are on antidepressants. That’s an eightfold increase since 2005.